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A B S T R A C T   
Background: In society at large, it is debated whether use of antipsychotic drugs is associated with increased or 
decreased mortality among patients with schizophrenia. Large register studies have demonstrated an increased 
mortality risk associated with non-use of antipsychotic drugs, but prospective studies are missing. 
Aims: To investigate the association between mortality and non-use of antipsychotics in patients with 
schizophrenia. 
Method: An open cohort study included and followed all patients with a discharge-diagnosis of schizophrenia 
consecutively admitted to a psychiatric acute unit at Haukeland University Hospital, Bergen, Norway during a 
10 year period (n = 696). Cox multiple regression analyses were conducted with use of antipsychotic drugs as a 
time dependent variable, and periods of use and non-use were compared within individual patients. Adjustments 
were made for gender, age at index admission, number of acute psychiatric hospital admissions, excessive use of 
alcohol and illicit substances and use of benzodiazepines and antidepressants. 
Results: A total of 68 (9.8%) deaths were registered during follow-up. Of these, 40 (59%) had natural causes, 
whereas 26 (38%) had unnatural causes. Non-use of antipsychotics was associated with 2.15 (p = .01, CI: 
1.24–3.72) times higher mortality risk compared to use of antipsychotics. The difference in mortality risk be-
tween use and non-use of antipsychotic drugs was age dependent, with the largest risk difference in young 
patients. 
Conclusions: Non-use of antipsychotic drugs was associated with twofold increased mortality risk in patients with 
schizophrenia.   
1. Introduction 
Schizophrenia is a serious mental disorder with a prevalence just 
below 1% (Janoutova et al., 2016; Kahn et al., 2015), and is associated 
with severe problems in many areas of life, including inability to work, 
social disability and drug abuse (Tandon et al., 2009). Antipsychotic 
drugs remain a cornerstone in treatment guidelines worldwide (Hasan 
et al., 2013; Lally and MacCabe, 2015), but treatment can be chal-
lenging, reflected by non-adherence rates as high as 40–75% (Lacro 
et al., 2002; Leucht and Heres, 2006). Recently, patient organizations 
have advocated for the need of psychosis treatment without antipsy-
chotic drugs. As a result, «medication-free» treatment services have 
been established within the Norwegian public health care system. 
Although some studies on psychosocial interventions for schizophrenia 
without the use of antipsychotic drugs have been conducted, the evi-
dence is generally of low quality (Cooper et al., 2020). Hence, there is an 
urgent need to evaluate the consequences of choosing not to use anti-
psychotic drugs. 
The mortality risk among patients with schizophrenia is considerably 
higher than in the general population (Heiberg et al., 2018; Nome and 
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Holsten, 2012), with reduced life expectancy reported in the range of 11 
to 20 years (Hjorthoj et al., 2017; Laursen et al., 2013). Increased risk of 
premature death from both natural and unnatural causes have been 
found, with cardiovascular disease (CVD), respiratory disease and sui-
cide being major causes (Olfson et al., 2015). Although reasons are likely 
to be multifactorial, spanning from genetic vulnerability to lifestyle 
factors (Andreassen et al., 2013), it is evident that common adverse 
effects of antipsychotic drugs such as obesity, dyslipidaemia, and dia-
betes contribute to the increased mortality risk (Mackin et al., 2007). 
Paradoxically, however, a great number of studies find a decreased risk 
of death associated with the use of antipsychotics compared to non-use, 
as demonstrated in a recent meta-analysis (Vermeulen et al., 2017). 
Methodological shortcomings of the studies, particularly related to their 
retrospective designs (Chen et al., 2019; Vermeulen et al., 2017), make 
them vulnerable to incomplete reporting of data and inadequate control 
for potentially confounding variables (De Hert et al., 2010; Thygesen 
and Ersboll, 2014). There is thus a need of prospective studies with pre- 
defined research questions and targeted data acquisition that account 
for crucial factors such as non-adherence and the high drug discontin-
uation rates. Accordingly, we aimed to investigate how use versus non- 
use of antipsychotic drugs is associated with mortality in a total-cohort 
of patients with schizophrenia consecutively admitted to a large psy-
chiatry acute unit. 
2. Material and methods 
2.1. Sample 
The study was conducted at the Division of Psychiatry, Haukeland 
University Hospital, Bergen, Norway. Haukeland University Hospital 
receives approximately 95% of all patients in need of acute psychiatric 
hospital admission from a catchment area of about 400,000 inhabitants. 
All patients consecutively admitted to the Psychiatry Acute Unit be-
tween May 1st 2005 and June 15th 2014, who met the criteria of a 
discharge ICD-10 (https://icd.who.int/browse10/2019/en) diagnosis of 
schizophrenia (F 20.0-F 20.9) were eligible for inclusion. As presented in 
Fig. 1, a total of 772 eligible patients were admitted during the 10-year 
period. Of these, 76 patients were excluded due to lack of information 
about the use of antipsychotic drugs after discharge. Accordingly, 696 
patients were included in the final sample. 
2.2. Procedure 
Patients with a diagnosis of schizophrenia were included at the first 
acute admission during the study period, hereby named the index 
admission. Clinicians who were involved in the assessment of patients at 
admission underwent training in the rating scales used. The patients 
were followed from the first day of the index-admission and until May 
1st 2015 or the date of death or censoring. Patients were censored when 
they moved out of the hospital catchment area (n = 48), or if they were 
lost to follow-up for other reasons (n = 142). If no information about the 
patients use or no-use of antipsychotic medication was available, the 
patient was censored after the last day of information. Data, including 
periods of use and periods of non-use of antipsychotic drugs, were 
collected from the medical records for each patient both during and in- 
between any hospital admissions. The study benefits from the complete 
and transparent public mental health system in Norway, which makes it 
possible to follow individual patients through the follow-up at different 
levels of care. Data on drug prescriptions and adherence during the 
periods in-between admissions were obtained retrospectively from the 
patients' medical records. Drug adherence in-between admissions was 
evaluated based on all available information from the patients, families, 
mental health care records and serum level measurements of antipsy-
chotic medications when available. To avoid discrepancy in how infor-
mation was obtained and registered, M.F.S. and M.K. did all the data 
extraction. Any questions regarding registrations were logged and dis-
cussed in the researcher team. In order to avoid overestimation of drug 
discontinuation, we allowed for periods of discontinuation lasting up to 
two weeks without registering a termination, as long as the drug was 
restarted. Data on death were obtained by linking the patients' 11-digit 
identity number to information from the Norwegian Cause of Death 
Registry (conducted November 14th 2016). Dates for moving out of the 
hospital's catchment area were recorded from the medical records. 
2.3. Measurements 
To reflect treatment periods with and without antipsychotic drugs, 
we recorded the use of as a time dependent variable, meaning that the 
variable may change for an individual patient during the follow-up 
period. The antipsychotic drug-variable was coded 1 for the time 
period a patient used antipsychotic drugs, and 0 otherwise. The term 
“non-use” of antipsychotic drugs included both patient non-adherence 
and clinician-guided drug discontinuation. Medications were classified 
according to the Anatomical Therapeutic Chemical- (ATC) system, and 
only antipsychotics primarily given on the indication of psychosis were 
counted. Included antipsychotic drugs were amisulpride, aripiprazole, 
clozapine, flupentixol, haloperidol, olanzapine, paliperidone, perphe-
nazine, pimozide, quetiapine, risperidone, sertindole, ziprasidone and 
zuclopenthixol. The use of alcohol and illicit substances were measured 
using the Alcohol Use Scale (AUS) and the Drug Use Scale (DUS), single- 
item clinician-rated indexes of alcohol and drug abuse (Drake et al., 
1996). Use is measured on a 5-point scale from no problems to extremely 
severe problems. In accordance with previous literature, a score of 3 or 
higher was classified as excessive use (Van Wormer, 2010). For patients 
with two or more admissions during the study period, the highest given 
score on AUS and DUS was used in the analyses. When values were 
missing (n = 30), the AUS and DUS score were set to 0. Acute psychiatric 
hospital admissions and the use of benzodiazepines and antidepressants 
were recorded as time dependent variables. The variables were coded 1 
if admitted to hospital or when benzodiazepines and antidepressants 
where used, and 0 otherwise. Acute psychiatric hospital admissions 
included inpatient treatment periods at Community Mental Health 
Centres (CMCH) directly following an acute admission. 
2.4. Statistics 
Cox regression models were used to analyse the effect of antipsy-
chotic drugs use on mortality, which was the primary endpoint of the 
study. In order to test the robustness of the results, both univariate and 
multivariate analyses were conducted. The models compare the 
continuous mortality risk of use versus non-use of antipsychotic drugs. 
The multivariate model adjusted for gender, age at index admission, 
acute psychiatric hospital admission, excessive use of alcohol and illicit 
substances and use of benzodiazepines and antidepressants. Sensitivity Fig. 1. Flow of patients through the study.  
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analyses including an interaction term between use of antipsychotic 
drugs and age were undertaken, as well as analyses in separate age 
categories. The statistical software R version 4.0.2 (https://www.r-pro 
ject.org/) and the package survival were used for the statistical ana-
lyses. The cox-proportional hazard assumption was checked using the 
cox.zph() function. 
2.5. Ethics 
The authors assert that all procedures contributing to this work 
comply with the ethical standards of the relevant national and institu-
tional committees on human experimentation and with the Helsinki 
Declaration of 1975, as revised in 2008. The study was approved by the 
Norwegian Social Science Data Service, the Norwegian Directorate of 
Health Care and the Regional Committee for Medical Research Ethics 
(Approval number REK 46004). Use of patient information without 
informed consent was authorized by these instances. 
3. Results 
Clinical and sociodemographic characteristics are presented in 
Table 1. On average, patients were followed for 4.6 years (SD = 3.1). The 
median number of admissions were 0.65 per year. Throughout the study 
period, 142 (20.4%) patients were censored due to lack of information 
about their use of antipsychotic medications. During follow-up, 48 
patients (6.9%) were censored because they moved out of the hospital's 
catchment area, and 68 patients (9.8%) died. A total of 40 patients 
(58.8%) died from natural causes and 26 (38.2%) died due to unnatural 
causes. The most frequent causes of death were cardiovascular disease 
and accidental poisoning for natural and unnatural death, respectively. 
Causes and age at time of death are presented in Table 2. 
Results of the Cox multivariate and univariate analyses are presented 
in Table 3. In the univariate analysis, there was a significant positive 
association between mortality and non-use of antipsychotic medications 
(Adjusted hazard ratio (AHR) = 2.31, p = .002 CI: 1.36–3.94), meaning 
that the risk of death at any timepoint is 2.31 times higher when anti-
psychotic drugs are not used compared to periods with antipsychotic 
drug use. There was also a positive association between mortality and 
age (AHR = 1.05, p < .001, CI: 1.03–1.06), meaning that mortality risk 
increases by 5% per year. No significant associations were found be-
tween mortality and gender, hospitalization, excessive use of alcohol, 
excessive use of illicit substances, use of benzodiazepines and use of 
antidepressants. Results of the multivariate analysis were not different 
from those in the univariate analyses, except gender, where a significant 
negative association was found between mortality and female gender in 
the multivariate analysis (AHR = 0.50, p = .01, CI: 0.30–0.87). 
Results of the sensitivity analysis including the interaction term be-
tween age and use of antipsychotic drugs are presented in Table 4. A 
significant negative association was found for the interaction effect be-
tween use of antipsychotic drugs and age (AHR = 0.95, p = .01, CI: 
0.92–0.99). As the interaction term reflects a linear slope, this means 
that the difference in mortality risk between use and non-use of anti-
psychotic drugs decreases by 5% per year. Results of the sensitivity 
analysis were not different from those in the main analysis. The signif-
icant positive association between mortality and non-use of antipsy-
chotic medications remained in the sensitivity analyses (AHR = 2.88, p 
< .001, CI: 1.60–5.20), the AHR estimate now referring to a patient at 
mean age (41.1 years). When the association between mortality and 
non-use of antipsychotics were investigated separately in different age 
categories, the direction for the interaction effect was supported, as the 
largest risk differences between use and non-use were found in the 
youngest patients. In the analyses for separate age categories, the 
strongest association between mortality and non-use of antipsychotic 
medications was found for patients under 30 years (AHR = 3.54, p = .02, 
CI: 1.18–10.56). For patients over 70 years, no significant association 
between mortality and non-use of antipsychotic drugs was found. Based 
on the interaction term, calculated AHR was 6.06 and 0.60 for a 25 year 
old and a 75 year old, respectively. Thus, the AHR estimate in the 
youngest age categories was smaller than that found by extrapolating 
the linear interaction term. Accordingly, the magnitude of the risk dif-
ference seemed to be overestimated by the interaction term in the 
Table 1 
Baseline characteristics of the sample (n = 696)a.   
N Percent 
Gender   
Male  431 61.9% 
Female  265 38.1% 
Receiving social benefits at index admission (n = 676)  612 90.5% 
Non-Norwegian ethnicity  85 12.2% 
Highest completed education (n = 617)   
Primary school, 7–9 years  335 54.3% 
Secondary school, 12 years  207 33.5% 
University or college  75 12.2% 
Previous treatment contact   
Outpatient care  41 5.9% 
Inpatient care  620 89.1% 
No previous treatment contact  35 5.0% 
Schizophrenia diagnosis at discharge from index admission   
F20.0  533 76.6% 
F20.1  50 7.2% 
F20.2  6 1.0% 
F20.3  40 5.7% 
F20.4–9  67 9.6% 
Comorbid alcohol or drug problem at index admission   
AUS score ≥ 3 (n = 618)  68 11.0% 
DUS score ≥ 3 (n = 625)  93 14.9% 
Comorbid ICD-10 diagnosis, F10.0-F19.9  97 13.9%    
Mean (range) SD 
Age at index admission 41.1 (16–92)  14.7 
N = number. 
SD = standard deviation. 
AUS = Alcohol Use Scale. 
DUS = Drug Use Scale. 
ICD10 diagnoses: 
F20.0 = paranoid schizophrenia. 
F20.1 = hebephrenic schizophrenia. 
F20.2 = catatonic schizophrenia. 
F20.3 = undifferentiated schizophrenia. 
F20.4–9 = post-schizophrenic depression, residual schizophrenia, simple 
schizophrenia, other schizophrenia and unspecified schizophrenia. 
F10.0-F19.9 = mental and behavioral disorders due to psychoactive substance 
abuse. 
a If values are missing, the total n is presented. 
Table 2 
Causes of mortality.   
N Percent 
Died during follow-up  68 9.8%a 
Natural death  40 58.8%b 
Neoplasms  7 10.3%b 
Cardiovascular disease  18 27.9%b 
Chronic lower respiratory disease  9 13.2%b 
Others  6 7.4%b 
Unnatural death  26 38.2%b 
Suicide  9 13.2%b 
Accidental poisoning  13 19.1%b 
Other accidents  4 5.9%b 
Unknown cause of death  2 2.9%b    
Mean (range) SD 
Age at time of death 51.3 (19–93)  17.8  
a Percent of total (n = 696). 
b Percent of deceased (n = 68). 
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In this cohort of acutely admitted patients with schizophrenia, non- 
use of antipsychotic drugs after discharge was associated with increased 
mortality risk. The risk difference between use and non-use of antipsy-
chotic drugs was age dependent, with the largest risk difference in young 
patients. The association between mortality and use versus non-use of 
antipsychotic drugs was analysed in a time dependent manner, and we 
are not aware of similar studies conducted in a consecutively included 
total-cohort. As even the most severely ill patients were included, our 
sample is representative for patients with schizophrenia discharged from 
hospital after an acute admission. 
It is generally assumed that common adverse effects of antipsychotic 
drugs such as obesity, dyslipidaemia, and diabetes mellitus contribute to 
premature mortality in schizophrenia (Mackin et al., 2007). Indeed, 
antipsychotics seem to increase the risk of myocardial infarction and 
cerebrovascular incidences (Correll et al., 2017; Yu et al., 2016). Rarely, 
antipsychotic drugs may cause malignant arrhythmias, myocarditis, 
thromboembolism and sudden cardiac death (Bellissima et al., 2018; 
Jonsson et al., 2018; Ray et al., 2009; Wu et al., 2015; Zhu et al., 2019). 
Some studies conducted in the era of first generation antipsychotic drugs 
have found an association between high exposure to antipsychotic drugs 
and increased mortality (Joukamaa et al., 2006; Waddington et al., 
1998). Further, first generation antipsychotics, but not second genera-
tion drugs, were found to be associated with increased mortality risk in a 
health insurer database (Tenback et al., 2012). Different mortality risk 
between antipsychotic drug classes may contribute to some inconsistent 
findings in old versus more recent studies, reflecting temporal different 
patterns of antipsychotic drug use and dosing across decades. A study by 
Torniainen et al. (Torniainen et al., 2015) also reported higher risk of 
death in patients with higher exposure to antipsychotic drugs compared 
to patients with low or moderate exposure. Paradoxically, the highest 
risk of death was found in patients that do not use antipsychotic drugs, 
suggesting that poor life-style and reduced capacity for health promot-
ing behaviour associated with untreated psychosis may outweigh the 
long-term adverse effects of antipsychotic drugs (Tiihonen et al., 2009). 
Our results are in line with the study by Torniainen et al. (Torniainen 
et al., 2015) as well as a large number of studies concluding that use of 
antipsychotic drugs decreases the mortality risk (Baxter et al., 2016; 
Crump et al., 2013; Cullen et al., 2013; Taipale et al., 2018; Tiihonen 
et al., 2011; Tiihonen et al., 2009; Tiihonen et al., 2016; Tiihonen et al., 
2006; Torniainen et al., 2015; Vermeulen et al., 2017). Completely in 
accordance with our findings, most of these studies report that non-use 
of antipsychotic drugs increases the mortality risk with a factor close to 
2. Reasons are most likely multifactorial, but may include that patients 
with untreated psychosis have a higher risk of suicide (Aydin et al., 
2019; Nielssen et al., 2012). Symptoms associated with psychosis, such 
as distorted perception of reality, disorganized thoughts, impulsivity 
and poor problem solving skills can compromise the patients' ability to 
perceive risks and protect themselves, and these patients are more likely 
to be involved in accidents and violent incidents (Teplin et al., 2005). 
Adding to this, studies have shown that CVD risk factors are not only 
associated with antipsychotic medications, but also with schizophrenia 
itself (Andreassen et al., 2013; Rajkumar et al., 2017). This association is 
extra unfortunate bearing in mind that patients with psychosis tend to 
seek medical care for somatic problems less often than the general 
population, and are likely to demonstrate poor understanding of phys-
ical illnesses and preventive behaviour (Kim et al., 2019; Swildens et al., 
2016). Thus, dampening of psychosis may facilitate a healthier lifestyle 
and more active health care-seeking behaviour in case of emerging so-
matic symptoms. Antipsychotic drugs may as such contribute to 
decreased risk of premature natural death. 
Moreover, the risk difference between use and non-use of antipsy-
chotic drugs was age dependent. The largest difference in mortality risk 
between use and non-use of antipsychotic drugs was found in the 
youngest age group. In previous studies, the highest standardized mor-
tality rates (SMR) have been found among the youngest patients with 
schizophrenia, with elderly patients having the lowest SMR (Piotrowski 
et al., 2017). Based on this, it may be plausible that any mortality risk- 
reducing effect of antipsychotic drugs is most pronounced in the youn-
gest age group, and with limited effect among the elderly. Indeed, no 
difference in mortality risk between use and non-use of antipsychotic 
drugs in elderly patients was found in our study. Interestingly, a recent 
systematic review on short-term mortality of second-generation anti-
psychotics found no evidence of increased mortality, except in elderly 
patients (Schneider-Thoma et al., 2018). Theoretically, the substantially 
reduced life expectancy found in schizophrenia may lead to survival 
bias, meaning that those who live to reach a high age represents a 
healthier subgroup. Any secondary beneficial effect of psychosis- 
reduction on life style and health seeking behaviour may therefore be 
Table 3 
Predictors of death.  
T Multivariate analysis Univariate analyses 
AHR 95% CI P- 
value 
HR 95%CI P- 
value 
Age at index 
admission, per 
year  
1.05 1.04–1.07  <.001  1.05 1.03–1.06  <.001 
Gender (male 
gender = 1)  
0.50 0.30–0.87  .01  0.68 0.40–1.15  .15 
Non-use of 
antipsychotic 
drugs (use = 1)  





1.37 0.71–2.65  .34  1.25 0.66–2.38  .49 
Excessive use of 
alcohola (no = 1)  
0.87 0.44–1.74  .69  1.02 0.58–1.79  .94 
Excessive use of 
illicit 
substancesb (no 
= 1)  
1.99 0.98–4.05  .06  1.19 0.69–2.07  .53 
Use of 
benzodiazepines 
(no = 1)  
1.27 0.68–2.35  .45  1.35 0.74–2.47  .33 
Use of 
antidepressants 
(no = 1)  
0.59 0.27–1.31  .20  0.48 0.22–1.05  .07 
AHR = adjusted hazard ratio. 
a AUS ≥ 3. 
b DUS ≥ 3. 
Table 4 
Predictors of death: sensitivity analysis including interaction term between age 
and use of antipsychotic drugs.  
T Multivariate analysis 
AHR 95% CI P- 
value 
Age at index admission, per year  1.07 1.05–1.09  <.001 
Gender (male gender = 1)  0.49 0.28–0.85  .01 
Non-use of antipsychotic drugs (use = 1)  2.88 1.60–5.20  <.001 
Interaction between age and use of antipsychotic 
drugs  
0.95 0.92.0.99  .01 
Acute psychiatric hospital admission (no = 1)  1.50 0.77–2.89  .23 
Excessive use of alcohola (no = 1)  0.90 0.45–1.81  .77 
Excessive use of illicit substancesb (no = 1)  1.84 0.90–3.77  .09 
Use of benzodiazepines (no = 1)  1.26 0.68–2.35  .46 
Use of antidepressants (no = 1)  0.63 0.28–1.39  .25 
AHR = adjusted hazard ratio. 
a AUS ≥ 3. 
b DUS ≥ 3. 
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less important in this sub-group, whereas long-term adverse antipsy-
chotic drug effects have relatively larger impact on mortality risk. 
Our results also indicate that gender is an important factor in regard 
to mortality. For women, the all-cause mortality risk was significantly 
lower compared to men (AHR = 0.5). Similar results are found in other 
studies in the field, where male gender has been associated with 
increased risk of both natural and unnatural death. Reasons for this 
gender differences are multifactorial, and studies have reported that 
cardiovascular mortality, lung cancer mortality and suicide are higher in 
men than in women (Olfson et al., 2015). 
4.1. Limitations and strengths 
Data collection such as ours will always involve some elements of 
subjectivity, but we have ensured transparent and rigorous methods of 
data collection by using defined algorithms in cases of doubt. In cases of 
uncertainty regarding the use of medications, the patients were 
censored. In the present study, the term “non-use” of antipsychotic drugs 
included both non- adherence and drug discontinuation guided by a 
clinician. We do not know how and to what extent non-adherence and 
sudden discontinuation of antipsychotic drugs may have affected our 
results. The mortality risk may be lower if the discontinuation of anti-
psychotic drugs is gradual under the supervision of a clinician. Poor drug 
adherence is not always discovered and described in the patients' med-
ical records, and it is possible that some of the patients on oral medi-
cations had a poorer adherence than registered. If so, that would 
indicate that “use of antipsychotic drugs” actually is a mix of use and 
non-use. As such, the differences found for mortality may represent 
underestimations. In accordance with other studies in the field, we 
allowed for periods of discontinuation lasting up to two weeks without 
recording a termination, as long as the drug was restarted (Mullins et al., 
2008; Sikka et al., 2005). This may also have caused an underestimation 
of the differences we found in mortality between use and non-use of 
antipsychotic drugs. Another limitation is the lack of information about 
the doses of the antipsychotic medications. 
We did not have information about the patients' somatic diseases, 
body mass index, blood pressure, cholesterol or smoking habits, which 
all are potential risk factors of premature death. It has been suggested 
that smoking may reduce extrapyramidal side-effects induced by anti-
psychotic medication (Sagud et al., 2009). Therefore, it is possible that 
use of antipsychotic drugs is associated with more smoking than non- 
use. Antipsychotic drugs are also associated with increased risks of 
diabetes, obesity and dyslipidaemia (Liebzeit et al., 2001; Mackin et al., 
2007; Stahl et al., 2009). Hence, as the burden of cardiovascular risk 
factors may be higher during use of antipsychotic drugs, the mortality 
difference attributed to use versus non-use of antipsychotic drugs may 
be underestimated. 
As a rule of thumb, the number of outcome events per predictor 
variable should be 10 or more in Cox regression models (Vittinghoff and 
McCulloch, 2007). We used 8 predictor variables in the main analysis, 
and the number of outcome events (deaths) was 68. This results in 8.5 
deaths per variable, which is not ideal from a statistical point of view. 
However, Vittinghoff et al. (Vittinghoff and McCulloch, 2007) 
concluded that 5–9 outcome events per variable are usually sufficient. 
Furthermore, results of univariate analyses were not different from those 
in the main analysis, except for gender. Gender was not significantly 
associated with mortality in the univariate analysis, probably due to 
higher mean age at time of index in women (44.1 years) than in men 
(39.3 years). Accordingly, there is little reason to assume that the results 
would be different with a lower number of predictor variables in the 
main analysis. 
The large and comprehensive sample and the long follow-up time are 
major strengths of the present study. In average, patients were followed 
for 4.6 years, and the maximum follow-up time was 10 years. As use of 
patient information without informed consent was authorized, all pa-
tients with a discharge-diagnosis of schizophrenia consecutively 
admitted to a large psychiatry acute unit was included in this total- 
cohort. Hence, even the most severely ill patients, who would other-
wise not be able to cooperate and consent, were included. Consequently, 
our sample is highly representative for patients with schizophrenia 
admitted to a psychiatric acute unit. As our sample includes all acutely 
admitted patients with schizophrenia, not only a selection, our study can 
be compared to nationwide register studies with larger sample sizes. 
However, it is important to emphasize that the majority of our partici-
pants had several relapses and readmissions. The median number of 
admissions were 0.65 per year, and our sample is therefore represen-
tative for the subgroup suffering from several relapses, but not neces-
sarily for all patients with schizophrenia, and particularly not those 
without the need for inpatient treatment. Hence, clinical and demo-
graphical characteristics of our sample may differ from those of studies 
with less severely ill patients. 
The reflection of the clinical reality where patients have periods on 
and off psychotropic drugs is another strength. Unlike most studies on 
mortality and use of antipsychotic drugs, we accounted for non- 
adherence and drug discontinuation, as well as important confounders 
such as use of alcohol, illicit substances, benzodiazepines and antide-
pressants. Accordingly, the present study is able to provide a good 
analysis of the association between antipsychotic drugs and death in 
patients with schizophrenia, and thus provide important information 
with regard to decision-making concerning use versus non-use of anti-
psychotic drugs for patients and their caretakers. 
5. Conclusion 
This study provides evidence that non-use of antipsychotic drugs is 
associated with more than twofold increased mortality risk in patients 
with schizophrenia. In the light of our findings, measures to optimise use 
of antipsychotic drugs should be strengthened and systematized. The 
increased mortality associated with non-use of antipsychotic drugs 
emphasizes the need for better psychoeducation, motivational work and 
tailored treatment that focuses on reduction of adverse effects. 
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